Andrew D. Campbell

Andrew D. Campbell

Auto-generated profile, based on publicly available information

Andrew D. Campbell

Cancer Research UK Scotland Institute, Glasgow, United Kingdom

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
ANArafath K. Najumudeen
Arafath K. Najumudeen
FCFatih Ceteci
Fatih Ceteci
SFSigrid K. Fey
Sigrid K. Fey
GHGregory Hamm
Gregory Hamm
RSRory T. Steven
Rory T. Steven
OSOwen Sansom
Owen Sansom

1 July 2016 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
SWSonja M. Wörmann
Sonja M. Wörmann
LSLiang Song
Liang Song
JAJiaoyu Ai
Jiaoyu Ai
KDKalliope Diakopoulos
Kalliope Diakopoulos
MKMagdalena U. Kurkowski
Magdalena U. Kurkowski
HAHana Algül
Hana Algül

13 November 2024 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
CKChristos Kiourtis
Christos Kiourtis
MTMaria Terradas-Terradas
Maria Terradas-Terradas
LGLucy M. Gee
Lucy M. Gee
SMStephanie May
Stephanie May
AGAnastasia Georgakopoulou
Anastasia Georgakopoulou
TBThomas G. Bird
Thomas G. Bird
Cellular senescence is not only associated with ageing but also impacts physiological and pathological processes, such as embryonic development and wound healing. Factors secreted by senescent cells affect their microenvironment and can induce spreading of senescence locally. Acute severe liver disease is associated with hepatocyte senescence and frequently progresses to multi-organ failure. Why the latter occurs is poorly understood. Here we demonstrate senescence development in extrahepatic organs and associated organ dysfunction in response to liver senescence using liver injury models and genetic models of hepatocyte-specific senescence. In patients with severe acute liver failure, we show that the extent of hepatocellular senescence predicts disease outcome, the need for liver transplantation and the occurrence of extrahepatic organ failure. We identify the TGFβ pathway as a critical mediator of systemic spread of senescence and demonstrate that TGFβ inhibition in vivo blocks senescence transmission to other organs, preventing liver senescence induced renal dysfunction. Our results highlight the systemic consequences of organ-specific senescence, which, independent of ageing, contributes to multi-organ dysfunction.

8 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
JLJoshua D. G. Leach
Joshua D. G. Leach
NVNikola Vlahov
Nikola Vlahov
PTPetros Tsantoulis
Petros Tsantoulis
RRRachel A. Ridgway
Rachel A. Ridgway
DFDustin J. Flanagan
Dustin J. Flanagan
DMDion Morton
Dion Morton
Right-sided (proximal) colorectal cancer (CRC) has a poor prognosis and a distinct mutational profile, characterized by oncogenic BRAF mutations and aberrations in mismatch repair and TGFβ signalling. Here, we describe a mouse model of right-sided colon cancer driven by oncogenic BRAF and loss of epithelial TGFβ-receptor signalling. The proximal colonic tumours that develop in this model exhibit a foetal-like progenitor phenotype (Ly6a/Sca1+) and, importantly, lack expression of Lgr5 and its associated intestinal stem cell signature. These features are recapitulated in human BRAF-mutant, right-sided CRCs and represent fundamental differences between left- and right-sided disease. Microbial-driven inflammation supports the initiation and progression of these tumours with foetal-like characteristics, consistent with their predilection for the microbe-rich right colon and their antibiotic sensitivity. While MAPK-pathway activating mutations drive this foetal-like signature via ERK-dependent activation of the transcriptional coactivator YAP, the same foetal-like transcriptional programs are also initiated by inflammation in a MAPK-independent manner. Importantly, in both contexts, epithelial TGFβ-receptor signalling is instrumental in suppressing the tumorigenic potential of these foetal-like progenitor cells.

14 August 2023 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
JVJohan Vande Voorde
Johan Vande Voorde
RSRory T. Steven
Rory T. Steven
ANArafath K. Najumudeen
Arafath K. Najumudeen
CFCatriona A. Ford
Catriona A. Ford
ADAlexander Dexter
Alexander Dexter
OSOwen Sansom
Owen Sansom
The genomic landscape of colorectal cancer (CRC) is shaped by inactivating mutations in tumour suppressors such as APC , and oncogenic mutations such as mutant KRAS . Here we used genetically engineered mouse models, and multimodal mass spectrometry-based metabolomics to study the impact of common genetic drivers of CRC on the metabolic landscape of the intestine. We show that untargeted metabolic profiling can be applied to stratify intestinal tissues according to underlying genetic alterations, and use mass spectrometry imaging to identify tumour, stromal and normal adjacent tissues. By identifying ions that drive variation between normal and transformed tissues, we found dysregulation of the methionine cycle to be a hallmark of APC-deficient CRC. Loss of Apc in the mouse intestine was found to be sufficient to drive expression of one of its enzymes, adenosylhomocysteinase (AHCY), which was also found to be transcriptionally upregulated in human CRC. Targeting of AHCY function impaired growth of APC-deficient organoids in vitro, and prevented the characteristic hyperproliferative/crypt progenitor phenotype driven by acute deletion of Apc in vivo, even in the context of mutant Kras . Finally, pharmacological inhibition of AHCY reduced intestinal tumour burden in Apc Min/+ mice indicating its potential as a metabolic drug target in CRC.

13 February 2024 in Nature Genetics
Verified
Journal Article
Open access
PDF file
SMSudhir B. Malla
Sudhir B. Malla
RBRyan M. Byrne
Ryan M. Byrne
MLMaxime W. Lafarge
Maxime W. Lafarge
SCShania M. Corry
Shania M. Corry
NFNatalie C. Fisher
Natalie C. Fisher
PDPhilip Dunne
Philip Dunne
Molecular stratification using gene-level transcriptional data has identified subtypes with distinctive genotypic and phenotypic traits, as exemplified by the consensus molecular subtypes (CMS) in colorectal cancer (CRC). Here, rather than gene-level data, we make use of gene ontology and biological activation state information for initial molecular class discovery. In doing so, we defined three pathway-derived subtypes (PDS) in CRC: PDS1 tumors, which are canonical/LGR5+ stem-rich, highly proliferative and display good prognosis; PDS2 tumors, which are regenerative/ANXA1+ stem-rich, with elevated stromal and immune tumor microenvironmental lineages; and PDS3 tumors, which represent a previously overlooked slow-cycling subset of tumors within CMS2 with reduced stem populations and increased differentiated lineages, particularly enterocytes and enteroendocrine cells, yet display the worst prognosis in locally advanced disease. These PDS3 phenotypic traits are evident across numerous bulk and single-cell datasets, and demark a series of subtle biological states that are currently under-represented in pre-clinical models and are not identified using existing subtyping classifiers.